Akorn wins FDA approval for ciprofloxacin HCl ophthalmic solution

Ciprofloxacin HCl ophthalmic solution is indicated for the treatment of infections caused by microorganisms in corneal ulcers and conjunctivitis. Akorn expects to launch ciprofloxacin in 2009.

Arthur Przybyl, president and CEO of Akorn, said: “This product approval represents our 20th product approval received in 2008, including our new drug application approval for Akten and our joint venture product approvals.

“I would like to personally congratulate our regulatory affairs department for their efforts. Of the 20 product approvals received in 2008, eight were launched in 2008 and 10 are scheduled for launch in the first half of 2009.”